ReviewThe Journal of investigative dermatology2018
JAK Inhibitors for Treatment of Alopecia Areata.
Review in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.JAMA network open · 2023Pooled it
- Global, Regional, and National Burden of Alopecia Areata and its Associated Comorbidities, 1990-2021, and Projections to 2050: An Analysis of the Global Burden of Disease Study 2021.Acta dermato-venereologica · 2025Article
- Vinegar-Processed Black Soybean Promotes Hair Growth and Prevents Alopecia via Wnt/β-Catenin Pathway.Food science & nutrition · 2025Article
- Sexual Dysfunction in Alopecia Areata: A Systematic Review.Journal of clinical medicine · 2025Review
- Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris.JAAD case reports · 2025Article
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database.The Journal of dermatology · 2024Article
- Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients.Acta dermato-venereologica · 2024Article
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series.Clinical, cosmetic and investigational dermatology · 2024Article
- Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.Acta dermato-venereologica · 2023Article
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature.JAAD case reports · 2023Article
- Review
- Article
- Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata.PNAS nexus · 2023Article
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date.Drugs in context · 2023Review
- JAK: Not Just Another Kinase.Molecular cancer therapeutics · 2022Review
- Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.JID innovations : skin science from molecules to population health · 2022Article
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases.Immune network · 2022Review
- Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice.Frontiers in immunology · 2022Article
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.Clinical, cosmetic and investigational dermatology · 2021Review
- Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model.The journal of investigative dermatology. Symposium proceedings · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The advancement of genetic and preclinical studies has uncovered the mechanisms involved in the pathogenesis of alopecia areata (AA). The development of targeted therapies using small molecules blocking specific pathways for the treatment of AA is underway. By repurposing Food and Drug Administration-approved small molecule JAK inhibitors as treatments for AA, it has been demonstrated that JAK inhibitors can effectively reverse hair loss in patients with moderate to severe AA. In this review, we summarize and discuss the current preclinical and clinical studies on JAK inhibitors, as well as the prospects of using JAK inhibitors for the treatment of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.